Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide: a new class Ic antidysrhythmic.

G H Smith

    Drug Intelligence & Clinical Pharmacy
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Flecainide acetate, a new oral antiarrhythmic drug, effectively treats complex ventricular arrhythmias and Wolff-Parkinson-White syndrome. It offers advantages over other treatments and is well-tolerated, supporting its addition to drug formularies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The 15 year ankle arthroplasty experience in a university hospital.

    Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons·2021
    Same author

    Concussion management application for amateur sports.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2017
    Same author

    Metal deposition patterns in central Scotland, as determined by Lichen transplants.

    Environmental monitoring and assessment·2013
    Same author

    Industrial air pollution by metals monitored by a synthetic fabric: A case study of a community.

    Environmental monitoring and assessment·2013
    Same author

    Multipotent PI-MECs are the true targets of MMTV-neu tumorigenesis.

    Oncogene·2012
    Same author

    Tensioning of Prolene reduces creep under cyclical load: relevance to a simple pre-operative manoeuvre.

    The Journal of hand surgery, European volume·2011
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Flecainide acetate is an orally active antiarrhythmic agent.
    • It is classified as a Class Ic antiarrhythmic drug.

    Purpose of the Study:

    • To evaluate the efficacy and safety of flecainide acetate.
    • To compare flecainide acetate with quinidine and disopyramide.

    Main Methods:

    • The study assessed flecainide's effect on various cardiac arrhythmias.
    • Pharmacokinetic properties including absorption and half-life were analyzed.
    • Adverse effects were documented.

    Main Results:

    • Flecainide acetate suppressed 88-100% of complex ventricular dysrhythmias.
    • It demonstrated superiority over quinidine and disopyramide in suppressing ventricular ectopic activity.

    Related Experiment Videos

  • The drug has a rapid absorption, a 13-hour half-life, and minimal hemodynamic impact.

    • Conclusions:

    • Flecainide acetate is effective for treating ventricular dysrhythmias and Wolff-Parkinson-White syndrome.
    • It is a well-tolerated, first-line oral agent with therapeutic advantages.
    • Consideration for addition to drug formularies is recommended.